IP Library › Patent Application 11415454

Patent Application

App. No. 11/415,454

Pyrid-2-one derivatives and methods of use

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 11/415,454

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also realtes to processes for making such compounds as well as to intermediates useful in such processes.

Claims (80)

1 . A method of inhibiting cell proliferation which comprises administering an effective amount of a compound of Formula I and ethyl 2-trifluoromethyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate

wherein A is O or S;

wherein Q is selected from —N(R 5 ) 2 , —NR 5 C(O)R 5 , —(C 1 -C 8 )alkyl-OR 5 , —(C 1 -C 8 )alkyl-S(O) n R 6 ,

substituted aryl, an unsubstituted or substituted monocyclic or bicyclic, non-aromatic carbocyclic ring, an unsubstituted or substituted monocyclic or bicyclic, heteroaryl ring, and an unsubstituted or substituted monocyclic or bicyclic, non-aromatic heterocyclic ring,

wherein a ring is unsubstituted or substituted with one or more groups selected from halo, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkynyl, (C 2 -C 8 )alkenyl, —OR 5 , —O—(CH 2 ) 1-2 —O—, —N(R 5 ) 2 , —(C 1 -C 8 )alkyl-N(R 5 ) 2 , (C 1 -C 8 )haloalkyl, lower cyanoalkyl, —(C 1 -C 8 )alkyl-OR 5 , lower alkylaminoalkoxy, lower aminoalkoxyalkyl, —(C 1 -C 8 )alkyl-S(O) n R 5 , —N(R 5 )—(C 1 -C 8 )alkyl-N(R 5 ) 2 , —N(R 5 )—(C 1 -C 8 )alkyl-OR 5 , —N(R 5 )—(C 1 -C 8 )alkyl-NHC(O)R 5 , —N(R 5 )—(C 1 -C 8 )alkyl-C(O)N(R 5 ) 2 , lower alkoxyalkyl, —S(O) n R 5 , —SO 2 NR 5 R 5 , —NR 5 S(O) n R 5 , cyano, nitro, optionally substituted (C 3 -C 10 )cycloalkyl, optionally substituted aryl, optionally substituted 4-7 membered heterocyclyl, optionally substituted phenoxyalkyl, optionally substituted heterocyclyloxyalkyl, —C(O)N(R 5 ) 2 , —CO 2 R 5 , —CO 2 N(R 5 ) 2 , —SO 2 NHC(O)R 5 , optionally substituted phenylalkyl, optionally substituted heterocyclylalkyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 and —C(O)R 5 ;

wherein W is selected from

wherein n is 0, 1 or 2;

wherein R 1 is selected from H, —OR 6 , halo, aryl, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )perfluoroalkyl, —NR 5 2 , —(C 1 -C 8 )alkyl-NR 5 2 , —(C 1 -C 8 )alkyl-OR 5 , —S(O) n -alkyl, —S(O) n -aryl, —S(O) n -heteroaryl, (C 3 -C 10 )cycloalkyl, nitro, heterocyclyl, —NR 5 SO 2 R 5 , —C(O)N(R 5 ) 2 , —CO 2 R 5 , —(CR 5 2 ) 1-8 aryl, —(CR 5 2 ) 1-8 heterocyclyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 , and —C(O)R 5 ; wherein R 1 and R 2 may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R 2 is selected from H, —OR 6 , halo, aryl, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )perfluoroalkyl, —NR 5 2 , —(C 1 -C 8 )alkyl-NR 5 2 , —(C 1 -C 8 )alkyl-OR 5 , —S(O) n -alkyl, —S(O) n -aryl, —S(O) n -heteroaryl, (C 3 -C 10 )cycloalkyl, nitro, heterocyclyl, —NR 5 SO 2 R 5 , —C(O)N(R 5 ) 2 , —CO 2 R 5 , —(CR 5 2 ) 1-8 aryl, —(CR 5 2 ) 1-8 heterocyclyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 , and —C(O)R 5 ;

wherein R 3 is selected from H, —OR 6 , halo, aryl, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )perfluoroalkyl, —NR 5 2 , —(C 1 -C 8 )alkyl-NR 5 2 , —(C 1 -C 8 )alkyl-OR 5 , —S(O) n -alkyl, —S(O) n -aryl, —S(O) n -heteroaryl, (C 3 -C 10 )cycloalkyl, nitro, heterocyclyl, —NR 5 SO 2 R 5 , —C(O)N(R 5 ) 2 , —CO 2 R 5 —(CR 5 2 ) 1-8 aryl, —(CR 5 2 ) 1-8 heterocyclyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 , and —C(O)R 5 ; wherein R 2 and R 3 may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R 4 is independently selected from H, and (C 1 -C 6 )alkyl;

wherein R 5 is independently selected from H, lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkyl-alkyl, lower alkyl amino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl; and

wherein R 6 is independently selected from lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl;

wherein each aryl, heteroaryl, cycloalkyl, and heterocyclyl moiety of any R 1 , R 2 , R 3 , R 5 , R 6 , and Q is optionally substituted with one or more groups selected from halo, —NH 2 , —OH, —CO 2 H, (C 1 -C 6 )alkylamino, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxyalkyl, (C 1 -C 6 )alkyl, di(C 1 -C 6 )alkylamino, phenyl, and heterocyclyl;

and pharmaceutically acceptable salts thereof;

provided R 1 is not CF 3 when R 2 is ethoxycarbonyl, when R 3 is H, when W is thiazol-4-yl and when Q is 4-pyridyl or 2-chloro-4-pyridyl; further provided Q is not 4-pyridyl, when W is thiazol-2-yl, when R 1 , R 3 , and R 2 are H; further provided Q is not 2-nitro-5-furyl when W is thiazol-2-yl, when R 1 is methyl, when R 3 is H, and when R 2 is H; further provided Q is not phenyl when W is thiazol-2-yl, when R 1 is methyl, when R 3 is methyl, and when R 2 is H; further provided Q is not phenyl, 3,4-diacetylphenyl or 3,4-dihydroxyphenyl, when W is thiazol-2-yl, when R 1 is H, when R 3 is H, and when R 2 is H; and further provided Q is not 3-cyano-6-methyl-2-oxo-1,2-dihydro-5-pyridyl, when W is thiazol-2-yl, when R 1 is methyl, when R 3 is H, and when R 2 is acetyl.

2 . A method of treating cancer which comprises administering an effective amount of a compound of Formula I and ethyl 2-trifluoromethyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate

wherein A is O or S;

wherein Q is selected from —N(R 5 ) 2 , —NR 5 C(O)R 5 , —(C 1 -C 8 )alkyl-OR 5 , —(C 1 -C 8 )alkyl-S(O) n R 6 ,

wherein a ring is unsubstituted or substituted with one or more groups selected from halo, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkynyl, (C 2 -C 8 )alkenyl, —OR 5 , —O—(CH 2 ) 1-2 —O—, —N(R 5 ) 2 , —(C 1 -C 8 )alkyl-N(R 5 ) 2 , (C 1 -C 8 )haloalkyl, lower cyanoalkyl, —(C 1 -C 8 )alkyl-OR 5 , lower alkylaminoalkoxy, lower aminoalkoxyalkyl, —(C 1 -C 8 )alkyl-S(O) n R 5 , —N(R 5 )—(C 1 -C 8 )alkyl-N(R 5 ) 2 , —N(R 5 )—(C 1 -C 8 )alkyl-OR 5 , —N(R 5 )—(C 1 -C 8 )alkyl-NHC(O)R 5 , —N(R 5 )—(C 1 -C 8 )alkyl-C(O)N(R 5 ) 2 , lower alkoxyalkyl, —S(O) n R 5 , —SO 2 NR 5 R 5 , —NR 5 S(O) n R 5 cyano, nitro, optionally substituted (C 3 -C 10 )cycloalkyl, optionally substituted aryl, optionally substituted 4-7 membered heterocyclyl, optionally substituted phenoxyalkyl, optionally substituted heterocyclyloxyalkyl, —C(O)N(R 5 ) 2 , —CO 2 R 5 , —CO 2 N(R 5 ) 2 , —SO 2 NHC(O)R 5 , optionally substituted phenylalkyl, optionally substituted heterocyclylalkyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 and —C(O)R 5 ;

wherein W is selected from

wherein n is 0, 1 or 2;

wherein R 1 is selected from H, —OR 6 , halo, aryl, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )perfluoroalkyl, —NR 5 2 , —(C 1 -C 8 )alkyl NR 5 2 , —(C 1 -C 8 )alkyl-OR 5 , —S(O) n -alkyl, —S(O) n -aryl, —S(O) n -heteroaryl, (C 3 -C 10 )cycloalkyl, nitro, heterocyclyl, —NR 5 SO 2 R 5 , —C(O)N(R 5 ) 2 , —CO 2 R 5 , —(CR 5 2 ) 1-8 aryl, —(CR 5 2 ) 1-8 heterocyclyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 , and —C(O)R 5 ; wherein R 1 and R 2 may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R 3 is selected from H, —OR 6 , halo, aryl, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )perfluoroalkyl, —NR 5 2 , —(C 1 -C 8 )alkyl-NR 5 2 , —(C 1 -C 8 )alkyl-OR 5 , —S(O) n -alkyl, —S(O) n -aryl, —S(O) n -heteroaryl, (C 3 -C 10 )cycloalkyl, nitro, heterocyclyl, —NR 5 SO 2 R 5 , —C(O)N(R 5 ) 2 , —CO 2 R 5 , —(CR 5 2 ) 1-8 aryl, —(CR 5 2 ) 1-8 heterocyclyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 , and —C(O)R 5 ; wherein R 2 and R 3 may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R 4 is independently selected from H, and (C 1 -C 6 )alkyl;

wherein R 5 is independently selected from H, lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl; and

and pharmaceutically acceptable salts thereof;

3 . A method of inhibiting a serine/threonine kinase which comprises administering an effective amount a compound of Formula I and ethyl 2-trifluoromethyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate

wherein A is O or S;

wherein Q is selected from —N(R 5 ) 2 , —NR 5 C(O)R 5 , —(C 1 -C 8 )alkyl-OR 5 , —(C 1 -C 8 )alkyl-S(O) n R 6 ,

wherein W is selected from

wherein n is 0, 1 or 2;

wherein R 3 is selected from H, —OR 6 , halo, aryl, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )perfluoroalkyl, —NR 5 2 , —(C 1 -C 8 )alkyl-NR 5 2 , —(C 1 -C 8 )alkyl-OR 5 , —S(O) n -alkyl, —S(O) n -aryl, —S(O) n -heteroaryl, (C 3 -C 10 )cycloalkyl, nitro, heterocyclyl, —NR 5 SO 2 R 5 , —C(O)N(R 5 ) 2 , —CO 2 R 5 , —(CR 5 2 ) 1-8 aryl, —(CR 5 2 ) 1-8 heterocyclyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 , and —C(O)R 5 ; wherein R 2 and R 3 may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R 4 is independently selected from H, and (C 1 -C 6 )alkyl;

wherein R 5 is independently selected from H, lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl; and

and pharmaceutically acceptable salts thereof,

4 . A method of treating a neurological disorder which comprises administering an effective amount a compound of Formula I and ethyl 2-trifluoromethyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate

wherein A is O or S;

wherein Q is selected from —N(R 5 ) 2 , —NR 5 C(O)R 5 , —(C 1 -C 8 )alkyl-OR 5 , —(C 1 -C 8 )alkyl-S(O) n R 6 ,

wherein a ring is unsubstituted or substituted with one or more groups selected from halo, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkynyl, (C 2 -C 8 )alkenyl, —OR 5 , —O—(CH 2 ) 1-2 —O—, —N(R 5 ) 2 , —(C 1 -C 8 )alkyl-N(R 5 ) 2 , (C 1 -C 8 )haloalkyl, lower cyanoalkyl, —(C 1 -C 8 )alkyl-OR 5 , lower alkylaminoalkoxy, lower aminoalkoxyalkyl, —(C 1 -C 8 )alkyl-S(O) n R 5 , —N(R 5 )—(C 1 -C 8 )alkyl-N(R 5 ) 2 , —N(R 5 )—(C 1 -C 8 )alkyl-OR 5 , —N(R 5 )—(C 1 -C 8 )alkyl-NHC(O)R 5 , —N(R 5 )—(C 1 -C 8 )alkyl-C(O)N(R 5 ) 2 , lower alkoxyalkyl, —S(O) n R 5 —SO 2 NR 5 R 5 , —NR 5 S(O) n R 5 cyano, nitro, optionally substituted (C 3 -C 10 )cycloalkyl, optionally substituted aryl, optionally substituted 4-7 membered heterocyclyl, optionally substituted phenoxyalkyl, optionally substituted heterocyclyloxyalkyl, —C(O)N(R 5 ) 2 , —CO 2 R 5 , —CO 2 N(R 5 ) 2 , —SO 2 NHC(O)R 5 , optionally substituted phenylalkyl, optionally substituted heterocyclylalkyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 and —C(O)R 5 ;

wherein W is selected from

wherein n is 0, 1 or 2;

wherein R 3 is selected from H, —OR 6 , halo, aryl, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 1 -C 8 )perfluoroalkyl, —NR 5 2 , —(C 1 -C 8 )alkyl-NR 5 2 , —(C 1 -C 8 )alkyl-OR 5 , —S(O) n -alkyl, —S(O) n -aryl, —S(O) n -heteroaryl, (C 3 -C 10 )cycloalkyl, nitro, heterocyclyl, —NR 5 SO 2 R 5 , —C(O)N(R 5 ) 2 , —CO 2 R 5 , —(CR 5 2 ) 1-8 aryl, —(CR 5 2 ) 1-8 heterocyclyl, —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —NR 5 CO 2 R 5 , and —C(O)R 5 ; wherein R 2 and R 3 may be joined to form a 5-10 membered saturated or partially unsaturated carbocyclic or heterocyclic ring;

wherein R 4 is independently selected from H, and (C 1 -C 6 )alkyl;

wherein R 5 is independently selected from H, lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl; and

wherein R 6 is independently selected from lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl;

and pharmaceutically acceptable salts thereof;

5 . A method of treating apoptosis comprising administering an effective amount a compound of Formula I and ethyl 2-trifluoromethyl-6-oxo-5-(2-(4-pyridyl)(1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate

wherein A is O or S;

wherein Q is selected from —N(R 5 ) 2 , —NR 5 C(OR 5 , —(C 1 -C 8 )alkyl-OR 5 , —(C 1 -C 8 )alkyl-S(O) n R 6 ,

wherein W is selected from

wherein n is 0, 1 or 2;

wherein R 4 is independently selected from H, and (C 1 -C 6 )alkyl;

wherein R 5 is independently selected from H, lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkyl-alkyl, lower alkylamino-lower alkyl, aryloxyalkyl, alkylcarbonylalkyl, and lower perfluoroalkyl; and

and pharmaceutically acceptable salts thereof;